ADMA Biologics, Inc. (ADMA)
| Previous close | 6.67 |
| Open | 6.71 |
| Bid | 6.63 x 800 |
| Ask | 6.68 x 400 |
| Day's range | 6.60 - 6.73 |
| 52-week range | 3.06 - 6.76 |
| Volume | |
| Avg. volume | 2,525,216 |
| Market cap | 1.541B |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.13 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.38 |
GlobeNewswireADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
Conference Call Scheduled for May 9, 2024, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report first quarter 2024 financial results on May 9, 2024, after the U.S. financial markets close. ADMA’s management team will host a live conference call
ZacksAdma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
ZacksWhat's in Store for ADMA Biologics (ADMA) in Q1 Earnings?
On ADMA Biologics' (ADMA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
